Offerings Archives - Page 120 of 166

1 minute read

Autolus Therapeutics’ Leukemia Trial Meets Primary Goal Of Remission Rate, Shares Fall After $150M Capital Raise

December 9, 8:43 AM

Autolus Therapeutics plc’s (NASDAQ:AUTL) Phase 2 pivotal FELIX trial of obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult Acute Lymphoblastic…

AUTL

1 minute read

ObsEva Approved On December 8, 2022 An Increase Of Its Share Capital Through The Issuance Of 20M Newly Registered Shares At An Issue Price Of 1/13 Of A Swiss Franc Each

By Benzinga Newsdesk

December 9, 3:07 AM

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 9, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN)))), a biopharmaceutical company

OBSV

2 minute read

Reported Late Thursday, Autolus Announces Pricing Of $150M Public Offering Of 75M American Depositary Shares, Representing 75M Ordinary Shares At A Price Of $2/ADS

By Benzinga Newsdesk

December 9, 2:51 AM

Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the pricing of its previously announced underwritten public

AUTL

2 minute read

Reported Late Thursday, Replimune Announces Pricing Of $225M Public Offering Of 5,374,486 Shares Of Common Stock At A Price Of $23.50/Share

By Benzinga Newsdesk

December 9, 2:49 AM

Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced the pricing of its public offering

REPL

2 minute read

Reported Late Thursday, Prometheus Biosciences Announces Pricing Of Public Upsized $500M Offering Of 4,545,455 Shares Of Common Stock At A Price Of $110/Share

By Benzinga Newsdesk

December 9, 2:42 AM

Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion

RXDX

2 minute read

Reported Late Thursday, Grom Social Enterprises Prices $5M Public Offering Of 1,415,682 Units At A Price Of $2.89/Unit

By Benzinga Newsdesk

December 9, 2:37 AM

Grom Social Enterprises, Inc. (NASDAQ:GROM) (the "Company"), today announced the pricing of a public offering of 1,415,682 units (the "Units") at a price to the public of $2.89 per Unit and

GROM

1 minute read

Bank Of America Files For Debt Shelf, Size Not Disclosed

By Michael Horton

December 8, 6:15 PM

-SEC Filing

BAC

1 minute read

Boston Omaha Corp. May Sell, From Time To Time, Shares Of Co’s Class A Common Stock Of Up To $100M

By Benzinga Newsdesk

December 8, 5:28 PM

- SEC Form8 Filing

BOC

1 minute read

Cabaletta Bio Announces $35 Million Offering

By Benzinga Newsdesk

December 8, 8:06 AM

Cabaletta Bio, Inc. ("Cabaletta" or the "Company") (NASDAQ:CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients

CABA

2 minute read

SAB Biotherapeutics Announces $7.9M Private Placement Of Common Stock At $1.08/Share

By Michael Horton

December 7, 6:17 PM

SAB Biotherapeutics (NASDAQ:SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for

SABS